Lundbeck neurology, generics news

The EU General Court upheld a decision from the European Commission to fine Lundbeck for anticompetitive activity related to Lundbeck’s antidepressant Celexa citalopram. The court said that the commission correctly found that Lundbeck’s agreements with four generic companies constituted “a buying-off of competition” and “a restriction of competition by object.” The commission said that under these pay-for-delay agreements, pharmaceutical companies pay generic companies to “stay out of the market.” ...